Sounds like they have so many wonderful plans... But Volcano is a little company that just made it into positive earnings territory, and doesn't want to overspend its way back to quarterly losses. That's good discipline, but it won't lead to spectacular gains.
OCT seems to be developing in a sadly predictable way. It is extremely cool; doctors love it, but really: FFR and IVUS give more useful information, cheaper. I expect it to be a huge success.